Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...

GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's ...

The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions ...

GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims ...

Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA ...